🟢 CUPR is trading 36.7% up today on FDA clearance for MEDIFLY and Nasdaq compliance

CUPR is trading at $5.38 (36.7% up today), extending a sharp rebound driven by significant regulatory and listing milestones.

• The rally is fueled by continued enthusiasm following FDA clearance for the company’s MEDIFLY Maggots wound-care product.
• Momentum remains strong as the company successfully avoided a Nasdaq delisting in early June, solidifying its compliance narrative.
• The price action appears driven by these stock-specific catalysts rather than broader market or crypto sentiment, which has remained flat-to-weak.